Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR)
Jacob, Sony, Dunn, Brianne L., Qureshi, Zaina P. , Bandarenko, Nicholas, Kwaan, Hau C. , Pandey, Dilip K. , McKoy, June M. , Barnato, Sara E., Winters, Jeffrey L. , Cursio, John , Weiss, Ivy, Raife, Thomas J. , Carey, Patricia M. , Kiss, Joseph E. , Danielson, Constance, Clark, William F. , Rock, Gail, Fujimura, Yoshihiro , Zheng, X. Long , Chen, Hao , Chen, Fei , Armstrong, John, Raisch, Dennis W., Bennett, Charles L. , Sarode, Ravi , Ortel, Thomas L. , Rock, Gail, Matsumoto, Masanori , Winters, Jeffrey L , Zheng, X Long

Seminars in Thrombosis and Hemostasis | October 30, 2012 | Volume: 38 | Issue: 08 | Pages: 845-853

10.1055/s-0032-1328894 | PMID 23111862 Get It

Operational Characteristics of 11 C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial Treatment
Mitchell, Christopher , Lowe, Val J. , Rangel, Laureano J. , Hung, Joseph C., Kwon, Eugene D., Karnes, R. Jeffrey

Journal of Urology | October 30, 2012 | Volume: 189 | Issue: 4 | Pages: 1308-1313

10.1016/j.juro.2012.10.069 | PMID 23123372 Get It

Percutaneous Renal Cryoablation After Partial Nephrectomy: Technical Feasibility, Complications and Outcomes
Hegg, Ryan, Schmit, Grant D. , Boorjian, Stephen A. , McDonald, Robert J. , Weisbrod, Adam J. , Callstrom, Matthew R. , Atwell, Thomas D. , Thompson, R. Houston, Kurup, A. Nicholas

Journal of Urology | October 30, 2012 | Volume: 189 | Issue: 4 | Pages: 1243-1248

10.1016/j.juro.2012.10.066 | PMID 23123377 Get It

Navigating the Difficult Robotic Assisted Pyeloplasty
Thiel, David D.

ISRN Urology | October 30, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-4

10.5402/2012/291235 | PMID 23213571 Get It

Pyeloplasty is the gold standard therapy for ureteropelvic junction obstruction. Robotic assisted pyeloplasty has been widely adopted by urologists with and without prior laparoscopic pyeloplasty experience. However, difficult situations encountered during robotic assisted pyeloplasty can significantly add to the difficulty of the operation. This paper provides tips for patient positioning, port placement, robot docking, and intraoperative dissection and repair in patients with the difficult situations of obesity, large floppy liver, difficult to reflect colon (transmesenteric pyeloplasty), crossing vessels, large calculi, and previous attempts at ureteropelvic junction repair. Techniques presented in this paper may aid in the successful completion of robotic assisted pyeloplasty in the face of the difficult situations noted above.
Myocardial Infarction After Hip Fracture Repair: A Population‐Based Study
Huddleston, Jeanne M. , Gullerud, Rachel E., Smither, F. Clay , Huddleston, P.M. , Phy, Michael, Melton, L. Joseph, Roger, Véronique L. , Larson, Dirk R. , Huddleston, Paul M

Journal of the American Geriatrics Society | October 30, 2012 | Volume: 60 | Issue: 11 | Pages: 2020-2026

10.1111/j.1532-5415.2012.04205.x | PMID 23110362 Get It

Objectives To quantify the occurrence of myocardial infarction ( MI ) occurring in the early postoperative period after surgical hip fracture repair and estimate the effect on 1‐year mortality. Design A population‐based, historical cohort study of individuals who underwent surgical repair of a hip fracture that used the computerized medical record linkage system of the R ochester E pidemiology P roject. Setting Academic and community hospitals, outpatient offices, and nursing homes in O lmsted C ounty, M innesota. Participants Over the 15‐year study period (1988–2002), 1,116 elderly adults underwent surgical repair of a hip fracture. Measurements At the end of the first 7 days after hip fracture repair, participants were classified into one of three groups: clinically verified MI (cv‐ MI ), subclinical myocardial ischemia, and no myocardial ischemia. One‐year mortality was compared between these groups. Multivariate models assessed risk factors for early postoperative cv‐ MI and 1‐year mortality. Results Within the first 7 days after hip fracture repair, 116 (10.4%) participants experienced cv‐ MI and 41 (3.7%) subclinical myocardial ischemia. Overall 1‐year mortality was 22%, with no difference between those with subclinical myocardial ischemia and those with no myocardial ischemia. One‐year mortality for those with cv‐ MI (35.8%) was significantly higher than for the other two groups. Occurrence of early postoperative cv‐ MI , male sex, and history of heart failure or dementia were independently associated with greater 1‐year mortality, whereas prefracture home residence and preoperative higher hemoglobin were protective. Conclusion Rates of early postoperative, cv‐ MI after hip fracture repair exceed rates after other major orthopedic surgeries and are independently associated with greater 1‐year mortality.
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
Pruthi, Sandhya , Rahman, Rakhshanda Layeequr

Cancers | October 30, 2012 | Volume: 4 | Issue: 4 | Pages: 1146-1160

10.3390/cancers4041146 | PMID 24213502 Get It

Women who are at high risk of breast cancer can be offered chemoprevention. Chemoprevention strategies have expanded over the past decade and include selective receptor modulator inhibitors and aromatase inhibitors. Physicians are expected to provide individualized risk assessments to identify high risk women who may be eligible for chemoprevention. It is prudent that physicians utilize a shared decision approach when counseling high risk women about their preventive options. Barriers and misperceptions however exist with patient and physician acceptance of chemoprevention and continue to impede uptake of chemoprevention as a strategy to reduce breast cancer risk. Programs to increase awareness and elucidate the barriers are critical for women to engage in cancer prevention and promote chemoprevention adherence.
A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity
Guidugli, Lucia, Singh, Namit , Thompson, James E. , Erding, Catherine A., Engel, Christoph , Schmutzler, Rita K., Nathanson, Katherine L. , Radice, Paolo , Tonin, Patricia N. , Lindor, Noralane M. , Goldgar, David E., Pankratz, V. Shane , Domchek, Susan M. , Singer, Christian F. , Couch, Fergus J. , Thompson, James R. , Radice, Paolo , Nathanson, Katherine L , Engel, Christoph

Cancer Research | October 30, 2012 | Volume: 73 | Issue: 1 | Pages: 265-275

10.1158/0008-5472.can-12-2081 | PMID 23108138 Get It

Abstract The relevance of many BRCA2 variants of uncertain significance (VUS) to breast cancer has not been determined due to limited genetic information from families carrying these alterations. Here, we classified six new variants as pathogenic or nonpathogenic by analysis of genetic information from families carrying 64 individual BRCA2 DNA binding domain (DBD) missense mutations using a multifactorial likelihood model of cancer causality. Next, we evaluated the use of a homology-directed DNA break repair (HDR) functional assay as a method for inferring the clinical relevance of VUS in the DBD of BRCA2 using 18 established nonpathogenic missense variants and all 13 established pathogenic missense mutations from the BRCA2 DBD. Compared with the known status of these variants based on the multifactorial likelihood model, the sensitivity of the HDR assay for pathogenic mutations was estimated at 100% [95% confidence interval (CI): 75.3%–100%] and specificity was estimated at 100% (95% CI: 81.5%–100%). A statistical classifier for predicting the probability of pathogenicity of BRCA2 DBD variants was developed using these functional results. When applied to 33 additional VUS, the classifier identified eight with 99% or more probability of nonpathogenicity and 18 with 99% or more probability of pathogenicity. Thus, in the absence of genetic evidence, a cell-based HDR assay can provide a probability of pathogenicity for all VUS in the BRCA2 DBD, suggesting that the assay can be used in combination with other information to determine the cancer relevance of BRCA2 VUS. Cancer Res; 73(1); 265–75. ©2012 AACR.
Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Geng, Huimin , Brennan, Sarah, Milne, Thomas A. , Chen, Wei‐Yi , Li, Yushan , Hurtz, Christian , Kweon, Soo-Mi, Zickl, Lynette, Shojaee, Seyedmehdi, Biswas, Debabrata, Yuan, Xin , Racevskis, Janis, Ketterling, Rhett P. , Luger, Selina M. , Tallman, Martin S. , Rowe, Jacob M. , Litzow, Mark R. , Allis, C. David, Müschen, Markus , Paietta, Elisabeth , Elemento, Olivier , Melnick, Ari , Neuberg, Donna , Huang, Chuanxin , Lazarus, Hillard M. , Guzmán, Mónica L. , Roeder, Robert G. , Melnick, Ari , Ketterling, Rhett P

Cancer Discovery | October 30, 2012 | Volume: 2 | Issue: 11 | Pages: 1004-1023

10.1158/2159-8290.cd-12-0208 | PMID 23107779 Get It

Abstract Genetic lesions such as BCR–ABL1, E2A–PBX1, and MLL rearrangements (MLLr) are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Leukemia oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype. We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets. We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial (ECOG E2993) and normal control B cells. In BCR–ABL1-positive B-ALLs, aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of IL2RA(CD25). The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of BCR–ABL1 status, suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs. In E2A–PBX1-positive B-ALLs, aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A–PBX1 chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), suggesting that E2A–PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype. MLLr B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6. Notably, BCL6 blockade or loss of function suppressed proliferation and survival of MLLr leukemia cells, suggesting BCL6-targeted therapy as a new therapeutic strategy for MLLr B-ALLs. Significance: We conducted the first integrative epigenomic study in adult B-ALLs, as a correlative study to the ECOG E2993 phase III clinical trial. This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation. We identify a novel clinically actionable biomarker in B-ALLs: IL2RA(CD25), which is linked with BCR–ABL1 and an inflammatory signaling network associated with chemotherapy resistance. We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr. Cancer Discov; 2(11); 1004–23. ©2012 AACR. Read the Commentary on this article by Cimmino and Aifantis, p. 976. This article is highlighted in the In This Issue feature, p. 961
Prevalence of buried Barrett’s metaplasia in patients before and after radiofrequency ablation
Yuan, Jay, Hernandez, Jeric, Ratuapli, Shiva K., Petris, Giovanni De , Lam‐Himlin, Dora , Burdick, George E., Pannala, Rahul , Ramirez, Francisco C. , Fleischer, David E., Ruff, Kevin

Endoscopy | October 30, 2012 | Volume: 44 | Issue: 11 | Pages: 993-997

10.1055/s-0032-1325678 | PMID 23108770 Get It

Response to Letter Regarding Article, “Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (A
Rosner, Gregg, Kirtane, Ajay J. , Généreux, Philippe, Cristea, Ecaterina , Weisz, Giora, Parise, Helen , Fahy, Martin, Stone, Gregg W. , Lansky, Alexandra J. , Mehran, Roxana , Gersh, Bernard J.

Circulation | October 29, 2012 | Volume: 126 | Issue: 18 | Pages: No page available

10.1161/circulationaha.112.137752 Get It